In liver cancer, CCT3 was elevated and co-interacted with the transcriptional co-activator YAP, which is negatively regulated by the Hippo pathway, and transcription factor CP2 (TFCP2), a Hippo-independent oncoprotein in liver cancer. This evidence concerns the gene CCT3 and liver cancer.